Procalcitonin-guided antibiotic therapy: An expert consensus by Bartoletti, M. et al.
Clin Chem Lab Med 2018; 56(8): 1223–1229
Opinion Paper
Michele Bartoletti*, Massimo Antonelli, Francesco Arturo Bruno Blasi, Ivo Casagranda, 
Arturo Chieregato, Roberto Fumagalli, Massimo Girardis, Filippo Pieralli, Mario Plebani, 
Gian Maria Rossolini, Massimo Sartelli, Bruno Viaggi, Pierluigi Viale, Claudio Viscoli  
and Federico Pea
Procalcitonin-guided antibiotic therapy: an expert 
consensus
https://doi.org/10.1515/cclm-2018-0259
Received March 12, 2018; accepted March 23, 2018; previously 
 published online June 6, 2018
Abstract
Background: Procalcitonin (PCT) is a useful biomarker 
of bacterial infection and its use is associated to reduced 
duration of antibiotic therapy in the setting of intensive 
care medicine. To address the need of practical guidance 
for the use of PCT in various clinical settings, a group of 
experts was invited to participate at a consensus process 
with the aims of defining the rationale for appropriate use 
of PCT and for improving the management of critically ill 
patients with sepsis.
Methods: A group of 14 experts from anesthesiology and 
critical care, infectious diseases, internal medicine, pul-
monology, clinical microbiology, laboratory medicine, 
clinical pharmacology and methodology provided expert 
opinion through a modified Delphi process, after a com-
prehensive literature review.
Results: The appropriateness of use of PCT in terms of 
diagnosis, prognosis and antimicrobial stewardship was 
assessed for different scenarios or settings such us man-
agement of infection in the emergency department, regular 
wards, surgical wards or in the intensive care unit. Similarly, 
appropriateness and timing of PCT measurement were eval-
uated. All the process consisted in three Delphi rounds.
Conclusions: PCT use is appropriate in algorithms for 
antibiotic de-escalation and discontinuation. In this 
case, reproducible, high sensitive assays should be used. 
However, initiation or escalation of antibiotic therapy in 
specific scenarios, including acute respiratory infections, 
should not be based solely on PCT serum levels. Clinical 
and radiological findings, evaluation of severity of illness 
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and of patient’s characteristics should be taken into 
proper account in order to correctly interpret PCT results.
Keywords: antibiotic therapy; antimicrobial stewardship; 
expert consensus; procalcitonin.
Introduction
The growing prevalence of antibiotic resistance is a 
global emergence. It is estimated that, by 2050, 10 million 
people will die every year due to antimicrobial resistance 
[1]. The reason of antibiotic crisis relies on several factors, 
including the antibiotic misuse or overuse. In fact, it is 
reported that treatment indication, doses or duration of 
treatment are incorrect in up to 30%–50% of antibiotic 
prescriptions [2–4]. The over prescription of antibiotic, 
in turn, may be associated to increased costs, adverse 
events and prolonged length of hospitalization. On the 
other hand, early antibiotic prescription may be neces-
sary in patients with sepsis or septic shock [5]. In several 
studies on critically ill patients, any delay of adequate 
antibiotic treatment was associated to an increased risk 
for mortality [6, 7].
Procalcitonin (PCT) is a calcitonin precursor ubiqui-
tously distributed in the human organs and tissues [8]. 
Several characteristics have conferred to PCT a key role 
as a biomarker of bacterial sepsis. First, during the acute 
phase of sepsis, PCT production is commonly upregulated 
[9]. Second, peak levels of PCT after a bacterial insult are 
usually achieved very rapidly with values that are cor-
related with the intensity of the stimulation [10]. Third, 
PCT has a short half-life, and therefore levels usually 
drop rapidly after the end of the insult. According with 
these characteristics, previous studies indicate that PCT 
is a marker of bacterial infection with good sensitivity and 
specificity [9, 11, 12]. In addition, use of PCT was associ-
ated to lower antibiotic use, being able to rule out bacte-
rial infectious processes or to identify patients eligible to 
early antibiotic de-escalation or discontinuation [13, 14].
Despite the aforementioned encouraging results, the 
proper use of PCT should be further addressed in several 
specific clinical situations. More specifically, the effect 
of implementation of PCT algorithms in different clinical 
scenarios to improve antibiotic use and outcomes and to 
limit cost remains unknown [15]. To address the need of 
practical guidance for the use of PCT in various clinical 
settings, a group of experts was invited to participate at a 
consensus process with the aims of defining the rationale 
for appropriate use of PCT and for improving the manage-
ment of critically ill patients with sepsis.
Materials and methods
The consensus was managed by a multidisciplinary team, 
including experts in anesthesiology and critical care, infec-
tious diseases, internal medicine, pulmonology, clinical 
microbiology, laboratory medicine, clinical pharmacology 
and methodology (Table 1). Expert opinion from the board 
was obtained through a modified Delphi process [16].
Consensus process
The process was conducted on January 2017. The opinion 
of experts about the appropriateness of use of PCT was 
assessed in different clinical settings. In addition, the 
judgment of experts about the role of PCT as a diagnostic 
test, prognostic marker or as an antimicrobial steward-
ship tool was assessed as well. It consisted in a series of 
rounds as follows. During the first round, the experts were 
invited to share their opinion based on their knowledge 
and experiences. Thereafter, a free discussion and a com-
prehensive review of the literature was promoted. During 
the literature review process, only studies using high sen-
sitive assays (B·R·A·H·M·S· PCT antibodies assays) were 
included. These assays have shown reproducibility of 
results and great reliability.
On the first round, two experts, one of infectious disease 
and the other of clinical pharmacology, developed a list of 
questions and of possible predefined answers, which had 
to be submitted to the panel. The questions were directed 
to assess the appropriateness of use of PCT in different set-
tings, including emergency department (ED), intensive care 
unit (ICU) and internal medicine ward counting of pulmo-
nology and infectious disease department. The preestab-
lished answers included at first step a dichotomous choice 
(i.e. yes or no) with a secondary choice that motivated the 
answer based on expert opinion, relevant clinical trials or 
both of them. During the second round, the panel of expert 
answered the questions anonymously without any influence 
of group’s opinions. After a free discussion and reading the 
answers, a third round was conducted in which the experts 
reviewed their answers and had the opportunity to change it 
according with the view of the board’s response.
Consensus was defined with a cutoff of agreement 
≥80%. According with the agreement reached on indica-
tion and level of evidence, the recommendation for use or 
not use of PCT in different scenarios was classified with 
three levels of certainty following the National Institute 
for Health and Clinical Excellence guidelines: (i) “must” 
and “must not”, (ii) “should” and “should not” and (iii) 
“could” [17].
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Results
The opinion of experts about the appropriateness of use 
of PCT was assessed in different clinical settings. In addi-
tion, the judgment of experts about the role of PCT as a 
diagnostic test, prognostic marker or an antimicrobial 
stewardship tool was assessed.
General considerations
 – Careful evaluation of clinical and radiological find-
ings, evaluation of severity of illness and of patient’s 
characteristics should be taken into proper account in 
order to correctly interpret PCT results.
 – In patients with diagnosis of infection, PCT should 
be used to identify patients with poor prognosis. In 
this case, the trend of serum concentrations over time 
is more accurate than a single measurement. The 
usual cutoff for diagnosis of sepsis (>0.5 ng/mL) is 
inaccurate and should be tailored for specific setting, 
site of infection and severity of underlying disease.
Emergency department [18–24]
 – According with experts’ opinion, in the setting of ED 
and/or emergency room, PCT should be used to differ-
entiate bacterial infections from non-bacterial ones or 
from non-infectious processes. Thus, PCT should be 
included among the available biochemical laboratory 
tests that may be required in the urgency/emergency 
settings.
Internal medicine, pulmonology and infec-
tious disease departments [14, 21, 25–31]
 – In non-critically ill patients admitted in general 
wards, such us internal medicine department or 
Table 1: List of all members of the expert board.
Name   Affiliation   Role   Field of expertise
Massimo 
Antonelli
  UOC Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica (UOC) 
Fondazione Policlicnico Universitario A. Gemelli-Università Cattolica del 
Sacro Cuore
  Expert   Intensive care medicine
Francesco Bruno 
Arturo Blasi
  Department of Pathophysiology and Transplantation, Università degli 
studi di Milano, UOC broncopneumologia, IRCCS Fondazione, “Cà Granda” 
Policlinico, Milan, Italy
  Expert   Pulmonology
Ivo Casagranda   Dipartimento di Emergenza ed Accettazione, Azienda Ospedaliera “Santi 
Antonio e Biagio e C. Arrigo”, Alessandria
  Expert   Emergency
Arturo Chieregato   Neurorianimazione, Ospedale Niguarda Ca’ Granda, Milano   Expert   Neurological intensive 
care medicine
Roberto Fumagalli  Anestesia e rianimazione I, Ospedale Niguarda Ca’ Granda, Milano   Expert   Intensive care medicine
Massimo Girardis   Anestesia e Rianimazione I, Dipartimento chirurgia generale e  
specialità chirurgiche, Azienda Ospedaliero-Universitaria di  
Modena – Policlinico, Modena
  Expert   Intensive care medicine
Federico Pea   Institute of Clinical Pharmacology, Santa Maria della Misericordia University 
Hospital of Udine, ASUIUD, Udine, Italy;
Department of Medicine, University of Udine, Udine, Italy
  Facilitator   Clinical pharmacology
Filippo Pieralli   Subintensiva di Medicina, – Azienda Ospedaliero Universitaria Careggi – 
Firenze
  Expert   Internal medicine
Mario Plebani   UO Medicina di Laboratorio, Azienda Ospedale-Università di Padova, Padova  Expert   Laboratory medicine
Gian Maria 
Rossolini
  Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze e 
SOD Microbiologia e Virologia- Azienda Ospedaliero Universitaria Careggi 
– Firenze
  Expert   Clinical microbiology
Massimo Sartelli   UO Chirurgia Generale, Dipartimento Chirurgia maggiore oncologica, 
Ospedale di Macerata, Macerata
  Expert   Abdominal surgery
Bruno Viaggi   NeuroAnestesia e Rianimazione, Dipartimento di Anestesia, Azienda 
Ospedaliero Universitaria Careggi – Firenze
  Expert   Intensive care medicine
Neurological intensive 
care medicine
Pierluigi Viale   UO Malattie Infettive, Policlinico S.Orsola Malpighi, Bologna   Facilitator   Infectious disease
Claudio Viscoli   Clinica Malattie Infettive, Università di Genova e Ospedale Policlinico San 
Martino, IRCCS per l’Oncologia
  Expert   Infectious disease
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infectious disease department, PCT should be used 
in the diagnosis of bacterial infections that may need 
prompt antibiotic treatment.
 – In patients with community-acquired  pneumonia, 
not  fulfilling criteria for sepsis or septic shock PCT 
could be used to support starting of antibiotic 
treatment.
 – In patients with acute exacerbation of chronic 
obstructive pulmonary disease (COPD), PCT could be 
useful in the diagnosis of bacterial superinfection.
 – In patients with community-acquired pneumonia, not 
fulfilling criteria for sepsis or septic shock PCT could 
be used as a prognostic marker of worse outcome.
 – In non-critically ill patients, a PCT increase after 
48 h of antibiotic therapy must not justify treatment 
escalation.
 – In this setting, PCT level should be monitored over 
time to guide treatment discontinuation.
ICU or critically ill patients [11–13, 29, 32, 33]
 – In critical care medicine, PCT should be used to iden-
tify patients who need prompt antibiotic treatment.
 – In addition, PCT should be used to identify patients 
with poor prognosis. In this latter case, PCT serum 
level trend must be analyzed over time. However, the 
time frame between two consecutive samples should 
be tailored on different clinical scenarios.
 – In critically ill patients, a PCT increase after 48 h of 
antibiotic therapy must not be used to support treat-
ment escalation.
 – In ICU, PCT must be included as a tool in an algorithm 
for antimicrobial stewardship. Monitoring PCT lev-
els over time must guide the discontinuation and its 
timing.
 – In ICU, PCT must be used also in patients undergo-
ing renal replacement therapy. However, PCT results 
should be interpreted cautiously and in accordance 
with clinical, radiological, microbiological and bio-
humoral findings.
Surgical patients and patients with 
 intra-abdominal infections [34–38]
 – In patients undergoing surgical intervention for intra-
abdominal infections, PCT should be used to guide 
the duration of antibiotic treatment even in presence 
of suspicion of postoperative peritonitis.
 – Conversely, in postsurgical patients with intra-
abdominal infections, a worsening trend of PCT 
over time should be used for supporting the need of 
reintervention.
 – In patients with acute necrotizing pancreatitis, 
monitoring of PCT levels over time should be used to 
support the need of antibiotic escalation or discon-
tinuation. However, in this setting, the most accurate 
cutoff level of PCT for supporting antibiotic escalation 
is still to be defined.
Discussion
In this expert consensus, we evaluated the usefulness and 
appropriateness of PCT measurement in different clinical 
scenarios. We also assessed the expert opinions about the 
role of PCT as a diagnostic and/or prognostic test, and as 
a tool for antimicrobial stewardship.
PCT is considered a helpful biomarker of bacterial 
infection and an early marker of sepsis in different  settings, 
including ED, regular wards, surgical wards and ICU [11, 
39]. In a previous meta-analysis including 30 reports and 
3244 patients, the overall sensitivity, specificity and area 
under the receiver operating characteristics (ROC) curve 
of PCT in the diagnosis of sepsis were 0.79, 0.77 and 0.85, 
respectively [12]. Despite the level of evidence suggested 
by the literature, the panel did not reach an agreement 
about the role of PCT in supporting the diagnosis of pneu-
monia or of bacterial superinfection in patients with acute 
exacerbation of COPD. In this setting, it was believed that 
clinical criteria, patient’s medical history and radiological 
findings should be preferred over the results of biomark-
ers. As stated before, this result may contribute to generate 
controversy in the role of PCT in the diagnosis of lower res-
piratory tract infections. In a previous multicenter study, 
patients with lower respiratory tract infections were ran-
domized to start and discontinue antibiotics according 
with a PCT predefined algorithm or with clinical decision. 
The overall antibiotic exposure was significantly lower in 
patients included in the PCT group, whereas the rate of 
adverse outcome was similar in the two groups [14]. The 
results of our consensus are in the line with current Infec-
tious Disease Society of America guidelines on hospital-
acquired pneumonia or ventilator associated pneumonia, 
which do not consider PCT as relevant in the decision 
process to start antibiotic treatment in this setting [40].
An important setting of PCT use may be for antimi-
crobial stewardship purposes in critically ill patients in 
order to reduce the length of antibiotic treatment [33]. In 
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a randomized trial including 621 critically ill non-surgical 
patients, PCT guidance was useful to reduce the duration 
of antibiotic treatment with no adverse events [13]. More-
over, in a recent trial, 1575 ICU patients were randomized 
to receive a PCT-based algorithm to guide antibiotic pre-
scription. In this group, a non-mandatory advice to dis-
continue antibiotics was given to all patients showing a 
PCT decrease ≥80% from the baseline or in those showing 
a serum PCT level ≤0.5 μg/L. This group showed signifi-
cantly lower antibiotic consumption and significantly 
lower 28-day and 1-year mortality rates [41]. The hypoth-
esis of the authors to explain this latter result was that 
PCT may enable to exclude the presence of bacterial 
infections leading to a more accurate diagnosis of non-
infectious processes. This observation was further con-
firmed by a metanalysis of randomized trials in patients 
with respiratory infections [42] and in secondary analysis 
of a Swiss randomized trial. In this latter study, among 
the patients with congestive heart failure randomized to 
the PCT group, those having a PCT lower than 0.25 μg/L 
showed significative lower rate of adverse outcome [18]. In 
addition to lowering the antibiotic consumption, several 
cost-effectiveness analyses demonstrated that use of PCT-
based algorithms is associated to decrease of both ICU and 
non-ICU length of stay [43] and overall hospital cost saving 
ranging from £368 to £3268 [19, 43]. Lastly, in a paper eval-
uating a cost-impact model based on meta-analysis data 
of randomized trials, the estimated cost savings produced 
by use PCT for acute respiratory infections compared with 
standard care in a cohort of 1 million of people could reach 
$700,000 [44].
An additional important result of this work was that in 
both ICU and non-ICU patients, an increase of PCT after 48 h 
of antibiotic treatment did not represent an indication for 
antibiotic escalation. In a Danish multicenter randomized 
trial, a PCT-based algorithm to escalate antibiotic treat-
ment was not associated to an increased survival rate. In 
addition, this strategy led to higher antibiotic consumption 
and longer ICU stay, and therefore it is not advisable [29]. 
However, a recent randomized multinational trial showed 
that a reduction of PCT value ≥80% from the baseline to 
day 4 of observation was associated to a reduction in 28-day 
mortality. In addition, this study evaluated short-term 
change of PCT as a predictor of mortality and found that 
patients who died within 28 days had an average increase 
of 30% of PCT value form baseline. By comparison, patient 
who survived did not show any PCT value increase. It worth 
to be noted that the results of this study were not available 
at the time when the consensus took place [31].
The optimal cutoff of PCT ensuring the best sensitivity 
and specificity for diagnosis of infection is still a matter 
of debate. For lower respiratory tract infection, cutoffs of 
0.15–0.25 μg/L are commonly considered adequate [14, 45]. 
However, different real-life experiences in patients with 
intra-abdominal infection and in ICU patients with blood-
stream infection suggest that higher cutoff should be con-
sidered in these settings [32, 37]. In this latter case, higher 
cutoff values may be helpful to differentiate between bac-
terial and fungal infections [46, 47]. It is worth noting that 
all the available literature was produced using the high 
sensitive assays based on B·R·A·H·M·S· PCT antibodies, 
which have demonstrated strong reproducibility [48, 49]. 
The reproducibility of results of these assays is important 
especially when PCT-based algorithms are implemented 
for antimicrobial stewardship purposes. In this case, strict 
cutoff values are commonly used to decide start or discon-
tinuation of antibiotic treatment.
Areas of further investigation and limitations
Further studies are needed to address several aspects 
of PCT use. Specific cutoff values should be investigated 
and identified particularly in intra-abdominal infections, 
including bacterial superinfections of acute necrotizing 
pancreatitis, taking into consideration the importance of a 
high analytical sensitivity of the assay used. Most of rand-
omized clinical trials have been conducted in patients with 
acute respiratory infections. Thus, the application of spe-
cific algorithms of treatment escalation or de-escalation in 
other clinical scenarios has still to be evaluated. In addi-
tion, immunocompromised patients have been excluded 
from most clinical trials, and therefore most of the avail-
able evidences, including the findings of this consensus 
work, cannot be applied to immunocompromised hosts.
In conclusion, in this expert consensus, several 
aspects of PCT use have been evaluated and addressed. 
The experts considered PCT as an important marker of bac-
terial infection in both ICU and non-ICU patients. Its use 
may be appropriate in algorithms for antibiotic de-esca-
lation and discontinuation. However, initiation or escala-
tion of antibiotic therapy in specific scenarios, including 
acute respiratory infections, should not be based solely 
on PCT serum levels. Overall, in every clinical scenario, 
careful evaluation of clinical and radiological findings, 
evaluation of severity of illness and of patient’s charac-
teristics should be taken into proper account in order to 
correctly interpret PCT results.
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